Teva Pharmaceutical Industries Ltd
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: Teva Pharmaceutical Industries Ltd stock price vs OPK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OPK's multiple
Needs EPS (TTM), OPK P/E.
Implied fair value · at Teva Pharmaceutical Industries Ltd's multiple
Needs EPS (TTM) is negative, Teva Pharmaceutical Industries Ltd P/E.
Engine logicTeva Pharmaceutical Industries Ltdvalued onOPK’smultiple
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Teva Pharmaceutical Industries Ltd Latest annual filing · OPK FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 64% equity / 36% debt · EV / Revenue 2.55x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LTD · implied price per share
Reporting currency could not be verified.
OPKO Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Teva Pharmaceutical Industries Ltd · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.54x
Net debt / EBITDA
Leverage against operating earnings
—
-3.03x
Cash and equivalents
Liquid reserves on the balance sheet
—
$364.41M
Total debt
Interest-bearing obligations outstanding
—
$687.93M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
Teva Pharmaceutical Industries Ltd vs AMRN
Sarepta Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd vs SRPT
Amphastar Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
Teva Pharmaceutical Industries Ltd vs SUPN
Harmony Biosciences Holdings, Inc.
Teva Pharmaceutical Industries Ltd vs HRMY
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.